Industry Pharmaceutical Type of business Private Company | Products Pharmaceuticals Founded 2009 | |
 | ||
Website | ||
SOM Innovation Biotech, S.L. (SOM Biotech), is a private pharmaceutical company based at the Barcelona Scientific Park, Barcelona, Catalonia, Spain. The company is focused on drug repositioning through its proprietary in silico technology, which identifies new biological activities of a given drug.
SOM Biotech' advanced pipeline includes two products already in clinical proof of concept in patients for the treatment of TTR Amyloidosis and Huntington’s disease (both rare diseases). SOM Biotech business model is based on different types of licensing and joint-venture agreements.
In 2013, SOM Biotech´s product for the treatment of Glioblastoma, SOM0777, was licensed to the pharmaceutical company Argon Pharma.
In 2014, SOM Biotech initiated a phase IIa proof of concept study in humans, regarding its compound SOM0226 for treatment of TTR Amyloidosis, with Vall d´Hebron Hospital in Barcelona. During the same year, the United States of America Food and Drug Administration (FDA) granted orphan drug designation to SOM0226.
Awards
SOM Biotech was the winner of the EntrepreneurXXI Grow 2013 award in biotechnology.